A Phase 1 Study of LY2523355 in Patients With Solid Cancer
Phase 1
20 Years
N/A
20 Years
N/A
Not Enrolling
Both
Solid Tumors
Both
Solid Tumors
Trial Information
A Phase 1 Study of LY2523355 in Patients With Solid Cancer
Inclusion Criteria:
- Histological and/or cytological evidence of solid tumors
- A diagnosis of advanced and/or metastatic solid tumors
- Patients who are refractory to standard therapy or for which no proven effective
therapy exists
- Written informed consent
- Appropriate bone marrow, hepatic and renal functions
- ECOG PS =< 1
Exclusion Criteria:
- Have serious preexisting complication
- Have active infection which requires intravenous antibiotics
- Have symptomatic central nervous system metastases
- Have current acute or chronic leukemia
- Have had an autologous or allogenic hematopoietic stem cell transplantation
- Have active multiple cancers
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Dose limiting toxicity based on the Common Terminology Criteria for Adverse Events v4.0
Safety Issue:
Yes
Principal Investigator
Senior Manager
Investigator Role:
Study Director
Investigator Affiliation:
Kyowa Hakko Kirin
Authority:
Japan: Ministry of Health, Labor and Welfare
Study ID:
2523355-001
NCT ID:
NCT01358019
Start Date:
May 2011
Completion Date:
January 2013
Related Keywords:
- Solid Tumors
Name | Location |
|---|
